The FDA has classified a recall of 2.5 million bottles of prednisolone acetate ophthalmic suspension, a common prescription steroid eye drop, as a Class II action due to the presence of foreign material in the product. The affected medication, manufactured by Lupin Limited in India and distributed by Lupin Pharmaceuticals Inc., was initially flagged for recall on June 4, 2026, with the FDA's formal classification finalized on June 30, 2026.

Prednisolone acetate is one of the most widely prescribed post-surgical eye drops in the United States. It's routinely used to reduce inflammation after cataract surgery, LASIK, and other eye procedures, and it's also prescribed to treat uveitis, allergic eye conditions, and other inflammatory disorders affecting the eye's surface and front structures.

Why Is This Recall Serious?

Eye drops are applied directly to the eye, a sensitive organ with rich blood supply and direct proximity to the brain. Any contamination of a sterile eye medication poses a real risk of irritation, infection, or injury at the application site. The presence of foreign material in a product that's supposed to be sterile represents a manufacturing failure, not a normal variation.

A Class II recall designation means the FDA has determined that use of the affected product may cause temporary or medically reversible adverse health consequences, though the probability of serious harm is considered remote. This is a middle-tier classification, more serious than a Class III recall but below the Class I designation reserved for products likely to cause serious injury or death.

The specific nature of the foreign material has not been publicly disclosed by Lupin or the FDA. This is typical in enforcement reports, where manufacturers usually describe the defect category without providing detailed characterization of the contaminant.

Which Bottles Are Affected?

The recall covers prednisolone acetate ophthalmic suspension USP, 1%, in three bottle sizes: 5 milliliters, 10 milliliters, and 15 milliliters. All three sizes are included in the recall. The affected lot numbers span dozens of batches with expiration dates ranging from July 2026 through March 2028, meaning bottles currently in pharmacies, medical offices, and patients' medicine cabinets may be included, even if they appear to have several months of shelf life remaining.

The recalled product was distributed nationwide with no geographic concentration of risk. It was available through retail pharmacies, hospital pharmacies, ophthalmology practices, and ambulatory surgery centers across all 50 states.

Who Is Most at Risk?

Patients most likely to have this medication in their possession include those who recently underwent eye surgery and those currently being treated for inflammatory eye conditions. If you received this medication after an eye procedure in the past several months, your bottle may fall within the recalled lot numbers.

• Post-surgical patients: People who recently had cataract surgery, LASIK, or other ocular surgical procedures, since prednisolone acetate is routinely prescribed post-operatively for several weeks.
• Patients with inflammatory conditions: Those being treated for uveitis, iritis, or other inflammatory conditions of the eye requiring corticosteroid therapy.
• Patients with allergic eye disease: Those managing allergic conjunctivitis or keratitis requiring steroid eye drops.
• Patients with complex eye history: Those with a single eye, corneal transplants, glaucoma drainage device surgery, or other complex ocular procedures where even minor complications could have serious consequences.

What Should You Do Right Now?

If you have one of the recalled bottles, do not continue using it. Contact your pharmacist or eye care provider immediately for a replacement. The FDA's enforcement report includes the full table of affected National Drug Code (NDC) numbers and lot numbers, which your pharmacist or eye care professional can use to verify whether your specific bottle is included.

Ophthalmologists and optometrists are the primary points of contact for patients who need guidance on affected bottles. The FDA has advised that use of the affected eye drops be stopped immediately by patients who have recalled product.

What If You've Already Used the Product?

If you have been using the recalled product and experienced unexpected redness, irritation, pain, vision changes, or discharge, contact your eye care provider promptly. You should also report the adverse event to the FDA's MedWatch system, which collects safety information about medications and medical devices.

Patients with corneal abrasions, post-surgical eyes with healing incisions, or existing inflammatory conditions may face heightened vulnerability to any extraneous material, so they should be especially vigilant about monitoring for symptoms.

How to Verify Your Medication

• Check the label: Look at your eye drop bottle for the manufacturer name (Lupin Pharmaceuticals Inc.) and the product name (prednisolone acetate ophthalmic suspension USP, 1%).
• Find your lot number: Locate the lot number on your bottle and cross-reference it against the FDA's enforcement report table, which lists all affected lot numbers and expiration dates.
• Contact your pharmacy: Call the pharmacy where you filled the prescription and ask them to verify whether your specific bottle is on the recall list using the NDC codes and lot numbers.
• Reach out to your eye doctor: If you received the medication directly from an ophthalmology or optometry practice, contact that office to confirm whether your bottle is affected.

Lupin Limited received FDA approval for these eye drops in August 2024, making this recall approximately 22 months after that approval. The company manufactures a broad portfolio of generic pharmaceutical products, including multiple ophthalmic preparations.

It's worth noting that a different prednisolone acetate product, Pred Mild (10 milliliters) manufactured by AbbVie Inc., was subject to a separate voluntary recall in late May 2026 due to failed stability specifications. That recall was classified as Class III and affected 2,736 bottles. These are two distinct products and two distinct recalls, so patients should verify which manufacturer made their prescription.